Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Other than the CEO change there is no news that I can discern, so consequently it looks like a simple technical breakout which does tend to attract buyers. Just my $.02.
-Fritz
The following table shows the largest shareholders in HALOZYME THERAPEUTICS INC COM (HALO) for the quarter ended September 30, 2019, listed by holding size. The list represents up to 50 of the largest holders in the company.
--------------------------------------------------------------------
Note: Unless otherwise mentioned the reporting date is 09/30/2019
--------------------------------------------------------------------
Institution Shares Shares % Last
Held Changed Held Report
--------------------------------------------------------------------
The Vanguard Group Inc. 12,987,035 (267,472) 8.876 06/30
BlackRock Fund Advisors 10,241,420 693,929 7.000 06/30
Bellevue Asset Management AG 8,247,860 8,247,860 5.637 06/30
Invesco Advisers Inc. 4,959,279 1,220,614 3.390 06/30
Iridian Asset Management LLC 4,851,229 (2,158,837) 3.316 06/30
SSgA Funds Management Inc. 4,428,475 474,592 3.027 06/30
Thrivent Investment Management 3,785,665 115,835 2.587 06/30
Pictet Asset Management SA 3,712,062 (189,509) 2.537 06/30
William Blair Investment Manag 3,538,927 3,134,003 2.419 06/30
Fidelity Management & Research 2,738,438 54,700 1.872 06/30
Snyder Capital Management LP 2,729,005 (97,596) 1.865 06/30
JPMorgan Investment Management 2,503,696 195,147 1.711 06/30
JPMorgan Asset Management (UK) 2,019,447 93,173 1.380 06/30
Artisan Partners LP 1,999,363 (56,033) 1.367 06/30
Geode Capital Management LLC 1,833,838 185,483 1.253 06/30
Northern Trust Investments In 1,790,475 8,377 1.224 06/30
First Eagle Investment Managem 1,696,275 (432,000) 1.159 06/30
PanAgora Asset Management Inc 1,309,959 81,579 0.895 06/30
Point72 Asset Management LP 1,187,660 1,187,660 0.812 06/30
Fisher Asset Management LLC 1,163,160 221,470 0.795 06/30
First Light Asset Management L 1,067,813 (403,685) 0.730 06/30
BlackRock Advisors LLC 1,044,045 134,086 0.714 06/30
Goldman Sachs Asset Management 1,005,867 (106,917) 0.687 06/30
Citadel Advisors LLC 928,692 310,599 0.635 06/30
Teachers Advisors LLC 910,093 176,576 0.622 06/30
New York State Common Retireme 907,353 (71,096) 0.620 06/30
Charles Schwab Investment Mana 885,353 44,072 0.605 09/30
Granite Investment Partners LL 856,563 (164,132) 0.585 06/30
Federated MDTA LLC 820,979 (10,349) 0.561 06/30
Elk Creek Partners LLC 809,955 21,254 0.554 06/30
DWS Investment GmbH 694,862 (160,488) 0.475 06/30
Candriam Belgium SA 610,079 19,500 0.417 06/30
TIAA-CREF Investment Managemen 575,988 49,192 0.394 06/30
D. E. Shaw & Co. LP 553,386 233,400 0.378 06/30
Lombard Odier Asset Management 550,000 550,000 0.376 06/30
American Century Investment Ma 540,775 120,441 0.370 06/30
Jacobs Levy Equity Management 529,598 68,420 0.362 06/30
BlackRock Investment Managemen 524,728 71,957 0.359 06/30
Marshall Wace LLP 513,083 467,136 0.351 06/30
Two Sigma Investments LP 481,418 460,454 0.329 06/30
SV Health Managers LLP 475,633 0 0.325 06/30
Renaissance Technologies LLC 458,600 (290,800) 0.313 06/30
Adage Capital Management LP 450,000 300,000 0.308 06/30
BlackRock Investment Managemen 445,429 6,923 0.304 06/30
AXA Investment Managers UK Ltd 436,419 8,202 0.298 06/30
Wells Fargo Bank NA (Private 431,975 242,683 0.295 06/30
Invesco Capital Management LLC 428,130 (37,063) 0.293 06/30
Columbia Management Investment 406,387 157,702 0.278 06/30
Wells Capital Management Inc. 402,185 293,702 0.275 06/30
Goldman Sachs & Co. LLC (Priva 396,577 (3,122) 0.271 06/30
13F data provided by: Factset Research Systems Inc.;
Please send questions to ownership@factset.com.
Copyright, Factset Research Systems, 2019. All Rights Reserved.
(END) Dow Jones Newswires
October 20, 2019 03:50 ET (07:50 GMT)
That's hilarious. (EOM)
Climb? LMAO you're holding the chart upside down.
Watch and learn.
RS always happens by necessity when the ratio of AS/OS approaches 1.
It's like climate change. One can pretend it's not happening, but that would be unwise.
It was only for a second because that's when they reverse split the shares to bolster the price.
We'll see how silly I look when they do it again.
Heading sub-penny as all dilution scams do.
Thanks. December is but 8 weeks away. Should get interesting.
Thanks for the update, as I haven't gotten around to listening. I'm not overly concerned about SC Darzalex since I am not confident that I have a handle on the regulatory timetable.
Was there anything else of note or was it a rehash of the last few conferences?
-Fritz
It's a thoughtful analysis which I appreciate, but there is a flaw. It contains the assumption that Bruce's equity stake is viable and stable, i.e., that there is a business plan being executed to grow the company into a profitable entity.
That is certainly not the case here. Yes, a dilution scheme, (which by the way, this is a textbook case) would make his equity stake as worthless and untenable as any investors, but that IS the business plan. There is no other. This company is a cardboard cutout, a Potemkin Village, designed to make an appearance of a legit outfit. Everything is a prop in a theatrical production.
Before the last R/S, the AS and OS were, as now, in the tens of billions of shares. They printed and sold them all the way from $.05 down to sub-penny over a period of many months, tens of millions per day. So if you do THAT math, he and his thieving confederates are doing just fine.
Good luck!
-Fritz
So you are ok with the previous splits that wiped out the shareholders?
Bruce is making his bank on the dilution and selling of shares not on his "31% stake". Another reverse split will serve his interests not harm him.
Or it could be that it is a dilution scam heading for its third reverse split wiping out all current shareholders except the holders of the convertible debentures who will keep printing all day every day
Good luck with that
It sounds like the 60 day mark is only the deadline for a refusal to file determination.
How long would it usually take to get a decision from the date of filing?
SAN DIEGO, Sept. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint. The FeDeriCa study investigated a fixed-dose combination of pertuzumab (Perjeta®) and trastuzumab (Herceptin®) for subcutaneous administration using Halozyme's ENHANZE® drug delivery technology in combination with intravenous chemotherapy. The study results demonstrated non-inferior levels of Perjeta® in the blood (pharmacokinetics) compared to standard intravenous (IV) infusion of Perjeta® plus Herceptin® and chemotherapy in patients with HER2-positive early breast cancer.
"The results of the phase III FeDeriCa study represent an important development for our ENHANZE® drug delivery technology," said Dr. Helen Torley, President and CEO. "This is the first study to combine two therapeutic antibodies as a single fixed-dose subcutaneous formulation utilizing our ENHANZE® technology, thereby providing patients with HER2-positive breast cancer the possibility of a faster treatment option."
Subcutaneous administration of the fixed-dose combination of Perjeta® and Herceptin® is approximately 8 minutes for the initial loading dose and approximately 5 minutes for each subsequent maintenance dose. Intravenous administration is approximately 150 minutes for the loading dose of Perjeta® and Herceptin® using standard IV formulations and between 60-150 minutes for subsequent maintenance infusions for the combination.
The study also demonstrated that the safety profile of the fixed dose subcutaneous combination of Perjeta® and Herceptin® was consistent with the safety profile of Perjeta® and Herceptin® administered intravenously.
Full data from the FeDeriCa study will be submitted for presentation at an upcoming medical meeting and to health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).1 2
Helen gave a strong presentation today at the Wells Fargo Conference.
This smacks of the same type of desperate, deceptive and spurious "analysis" used in the past by the tobacco industry to demonstrate that cigs and cancer were not linked, and the charts and graphs employed today by climate change deniers. In fact if one follows the money behind these stories I'd bet that the petro-chemical industry is funding this new theme and inserting it into the gullible side of the press stream.
In terms of desperation they might as well trot out that ridiculous old Dow Chemical ad phrase from the 70s:
"Without chemicals, life itself would be impossible."
I think that is the most preposterously ridiculous thing I've read in a long time (outside of the daily Trump lie factory). Thanks for the laugh.
-Fritz
Heading sub penny as predicted and as was predictable
Yes! $.05 but only after a 100-1 reverse split. To the moon!
LMAO.
Sub-penny approaching. Don't say I didn't warn ya.
Good luck!
-Fritz
I wish him a long and rotten retirement, preferably spent in a very neglected adult diaper.
I'm pretty sure Third Security is R. Kirk FWIW. He's been selling for a while and has his own unique reasons.
IMO, institutional ownership is extremely substantial and minor variations are meaningless.
-Fritz
I don't see how $.02/share brings this to a ~$4.00/ share valuation.
-Fritz
They don't manufacture anything except more shares to sell.
The third RS is inevitable because this is a dilution machine.
-Fritz
Yes, I did listen this morning and agree that nothing new was disclosed. I don't agree that the market is skeptical. Today's action is on low volume and reflects larger market forces which are likely triggering margin calls, etc.
Also, I do think that the 2027 income estimate is reasonable. (BTW, Helen emphasized today that that figure does not include milestones).
We'll get 301 cancer news by Christmas time and that is now only 4 months away.
Lastly there was a continued emphasis on the prospect for new deals which can, and will, come at any time.
Good luck!
-Fritz
The new company is nevertheless still focused on generics so nothing has changed from broad a strategic point of view.
-Fritz
They are moving ahead with confidence.
Good luck!
-Fritz
Except many large institutions added substantially last quarter.
-Fritz
----------------------------------------------------
Revance Therapeutics Inc, Inst Holders, 2Q 2019 (RVNC)
4:20 am ET July 23, 2019 (Dow Jones)
The following table shows the largest shareholders in REVANCE THERAPEUTICS INC COM (RVNC) for the quarter ended June 30, 2019, listed by holding size. The list represents up to 50 of the largest holders in the company.
Note: Unless otherwise mentioned the reporting date is 06/30/2019
Institution Shares Shares % Last
Held Changed Held Report
Wellington Management Co. LLP 5,744,134 1,432,790 13.053 03/31
ArrowMark Colorado Holdings LL 3,409,217 1,098,314 7.747 03/31
Franklin Advisers Inc. 3,401,056 447,712 7.728 03/31
BlackRock Fund Advisors 3,035,703 236,990 6.898 03/31
JPMorgan Investment Management 2,479,095 90,371 5.633 03/31
AllianceBernstein LP 2,041,129 479,937 4.638 03/31
The Vanguard Group Inc. 2,025,107 347,663 4.602 03/31
Capital Research & Management 1,685,000 460,000 3.829 03/31
BNY Mellon Investment Adviser 1,278,024 (53,786) 2.904 03/31
JPMorgan Asset Management (UK) 1,136,922 13,393 2.584 03/31
Renaissance Technologies LLC 902,073 330,200 2.050 03/31
SSgA Funds Management Inc. 813,443 137,221 1.848 03/31
Mellon Investments Corp. 709,972 (211,109) 1.613 03/31
BAMCO Inc. 509,200 509,200 1.157 03/31
Northern Trust Investments In 498,934 70,584 1.134 03/31
Geode Capital Management LLC 488,347 102,529 1.110 03/31
DWS Investment GmbH 458,592 137,368 1.042 03/31
Dimensional Fund Advisors LP 373,904 148,196 0.850 03/31
Capital Research & Management 325,000 0 0.739 03/31
The Bank of New York Mellon Co 304,789 15,438 0.693 03/31
JPMorgan Chase Bank NA (Inves 281,833 (10,953) 0.640 03/31
Sio Capital Management LLC 254,581 86,857 0.579 03/31
Candriam Belgium SA 237,000 0 0.539 03/31
BlackRock Advisors LLC 231,415 70,718 0.526 03/31
Charles Schwab Investment Mana 225,381 48,353 0.512 06/30
Citadel Advisors LLC 206,451 194,862 0.469 03/31
Rhenman & Partners Asset Manag 193,181 0 0.439 03/31
BlackRock Investment Managemen 136,214 27,981 0.310 03/31
Columbia Management Investment 135,902 105,265 0.309 03/31
Rice Hall James & Associates 117,068 83,875 0.266 03/31
Two Sigma Investments LP 117,012 117,012 0.266 03/31
Principal Global Investors LLC 114,268 167 0.260 03/31
Teachers Advisors LLC 107,067 45,493 0.243 03/31
Morgan Stanley & Co. LLC 102,674 50,099 0.233 03/31
Goldman Sachs & Co. LLC (Priva 96,920 57,458 0.220 03/31
USAA Asset Management Co. 82,137 9,000 0.187 03/31
Vanguard Fiduciary Trust Co. 75,393 10,680 0.171 03/31
State of Wisconsin Investment 71,300 10,100 0.162 03/31
Merrill Lynch Pierce Fenner 69,944 33,167 0.159 03/31
Schweizerische Nationalbank (I 69,450 17,200 0.158 03/31
Fidelity Management & Research 64,300 (22,500) 0.146 03/31
TIAA-CREF Investment Managemen 64,068 6,423 0.146 03/31
QS Investors LLC 63,161 0 0.144 03/31
BlackRock Investment Managemen 60,126 2,288 0.137 03/31
California State Teachers' Ret 59,257 7,893 0.135 03/31
Parametric Portfolio Associate 57,405 4,787 0.130 03/31
Quinn Opportunity Partners LLC 56,672 0 0.129 03/31
The California Public Employee 51,755 0 0.118 03/31
RhumbLine Advisers LP 49,124 5,785 0.112 03/31
MFN Partners Management LP 46,000 0 0.105 03/31
13F data provided by: Factset Research Systems Inc.;
Please send questions to ownership@factset.com.
Copyright, Factset Research Systems, 2019. All Rights Reserved.
(END) Dow Jones Newswires
July 23, 2019 04:20 ET (08:20 GMT)
Revance Therapeutics Inc, Inst Holders, 2Q 2019 (RVNC)
4:20 am ET July 23, 2019 (Dow Jones)
The following table shows the largest shareholders in REVANCE THERAPEUTICS INC COM (RVNC) for the quarter ended June 30, 2019, listed by holding size. The list represents up to 50 of the largest holders in the company.
Note: Unless otherwise mentioned the reporting date is 06/30/2019
Institution Shares Shares % Last
Held Changed Held Report
Wellington Management Co. LLP 5,744,134 1,432,790 13.053 03/31
ArrowMark Colorado Holdings LL 3,409,217 1,098,314 7.747 03/31
Franklin Advisers Inc. 3,401,056 447,712 7.728 03/31
BlackRock Fund Advisors 3,035,703 236,990 6.898 03/31
JPMorgan Investment Management 2,479,095 90,371 5.633 03/31
AllianceBernstein LP 2,041,129 479,937 4.638 03/31
The Vanguard Group Inc. 2,025,107 347,663 4.602 03/31
Capital Research & Management 1,685,000 460,000 3.829 03/31
BNY Mellon Investment Adviser 1,278,024 (53,786) 2.904 03/31
JPMorgan Asset Management (UK) 1,136,922 13,393 2.584 03/31
Renaissance Technologies LLC 902,073 330,200 2.050 03/31
SSgA Funds Management Inc. 813,443 137,221 1.848 03/31
Mellon Investments Corp. 709,972 (211,109) 1.613 03/31
BAMCO Inc. 509,200 509,200 1.157 03/31
Northern Trust Investments In 498,934 70,584 1.134 03/31
Geode Capital Management LLC 488,347 102,529 1.110 03/31
DWS Investment GmbH 458,592 137,368 1.042 03/31
Dimensional Fund Advisors LP 373,904 148,196 0.850 03/31
Capital Research & Management 325,000 0 0.739 03/31
The Bank of New York Mellon Co 304,789 15,438 0.693 03/31
JPMorgan Chase Bank NA (Inves 281,833 (10,953) 0.640 03/31
Sio Capital Management LLC 254,581 86,857 0.579 03/31
Candriam Belgium SA 237,000 0 0.539 03/31
BlackRock Advisors LLC 231,415 70,718 0.526 03/31
Charles Schwab Investment Mana 225,381 48,353 0.512 06/30
Citadel Advisors LLC 206,451 194,862 0.469 03/31
Rhenman & Partners Asset Manag 193,181 0 0.439 03/31
BlackRock Investment Managemen 136,214 27,981 0.310 03/31
Columbia Management Investment 135,902 105,265 0.309 03/31
Rice Hall James & Associates 117,068 83,875 0.266 03/31
Two Sigma Investments LP 117,012 117,012 0.266 03/31
Principal Global Investors LLC 114,268 167 0.260 03/31
Teachers Advisors LLC 107,067 45,493 0.243 03/31
Morgan Stanley & Co. LLC 102,674 50,099 0.233 03/31
Goldman Sachs & Co. LLC (Priva 96,920 57,458 0.220 03/31
USAA Asset Management Co. 82,137 9,000 0.187 03/31
Vanguard Fiduciary Trust Co. 75,393 10,680 0.171 03/31
State of Wisconsin Investment 71,300 10,100 0.162 03/31
Merrill Lynch Pierce Fenner 69,944 33,167 0.159 03/31
Schweizerische Nationalbank (I 69,450 17,200 0.158 03/31
Fidelity Management & Research 64,300 (22,500) 0.146 03/31
TIAA-CREF Investment Managemen 64,068 6,423 0.146 03/31
QS Investors LLC 63,161 0 0.144 03/31
BlackRock Investment Managemen 60,126 2,288 0.137 03/31
California State Teachers' Ret 59,257 7,893 0.135 03/31
Parametric Portfolio Associate 57,405 4,787 0.130 03/31
Quinn Opportunity Partners LLC 56,672 0 0.129 03/31
The California Public Employee 51,755 0 0.118 03/31
RhumbLine Advisers LP 49,124 5,785 0.112 03/31
MFN Partners Management LP 46,000 0 0.105 03/31
13F data provided by: Factset Research Systems Inc.;
Please send questions to ownership@factset.com.
Copyright, Factset Research Systems, 2019. All Rights Reserved.
(END) Dow Jones Newswires
July 23, 2019 04:20 ET (08:20 GMT)
HALO Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALE...
Friday 19 July 2019
SAN DIEGO, July 19, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Janssen-Cilag International NV (Janssen) has submitted an extension application to the European Medicines Agency (EMA) for the subcutaneous delivery of DARZALEX® (daratumumab) for patients with multiple myeloma.
"We are pleased that Janssen's filing follows quickly after its filing last week of a Biologics License Application (BLA) with the U.S. Food and Drug Administration," said Dr. Helen Torley, President and CEO. "We are particularly excited that, pending approval by the EMA, a greater number of patients with multiple myeloma may soon have a new therapeutic option that offers the potential of DARZALEX® with a shorter administration time."
Janssen's submission follows the announcement of positive results from its Phase 3 COLUMBA study, which investigated subcutaneously administered DARZALEX® in comparison to intravenous DARZALEX® in patients with relapsed and refractory multiple myeloma. Subcutaneous DARZALEX®, using ENHANZE® drug delivery technology, was found to be non-inferior to intravenous DARZALEX® with regard to the co-primary endpoints of overall response rate and Maximum Ctrough concentration on day 1 of the third treatment cycle prior to dose.
HALO Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE®
Wednesday 17 July 2019
SAN DIEGO, July 17, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has dosed the first subject in a phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of efgartigimod (ARGX-113), using Halozyme's proprietary ENHANZE® drug delivery technology.
"Since the signing of our collaboration with argenx earlier this year, we have made strong progress and I am delighted that the first phase 1 trial has been initiated in such a short amount of time," said Dr. Helen Torley, President and CEO of Halozyme. "We look forward to expanding our work with argenx to bring the potential benefits of subcutaneous administration to more patients suffering from severe autoimmune diseases through our ENHANZE® technology."
Initiation of this study triggers a $5 million milestone payment to Halozyme during the current quarter under the global collaboration and license agreement between the two companies.
Agreed. The pegph20 cancer leg is a freebie if it works and won't cause long term grief if it doesn't.
Given the seriousness of the indication one could hope it would get a fast track review. Good news in any event.
-Fritz
If one has been been holding for years through multiple reverse splits one is far from flat. One is in in the House of Pain.